SMAD3 and Friedreich ataxia: Since pharmacological inhibition of the TGFβ pathway improves bone marrow dysfunction, we hypothesized that a mouse model with disruption of Fancd2 and Smad3, the canonical mediator of the TGFβ pathway, would overcome this FA hematopoietic defect and perhaps increase the survival of DKO newborn mice.